SOURCE: Theravance, Inc.

Theravance, Inc.

September 02, 2009 16:05 ET

Theravance to Present at Investor Conferences in September 2009

SOUTH SAN FRANCISCO, CA--(Marketwire - September 2, 2009) - Theravance, Inc. (NASDAQ: THRX) announced today that Theravance management is scheduled to present at the following investor conferences in September 2009:

Thomas Weisel Partners Healthcare Conference 2009
Four Seasons Hotel, Boston, MA
Wednesday, September 9, 2009
10:20 a.m. ET
Rick E Winningham, Chief Executive Officer

Robert Baird 2009 Healthcare Conference
Four Seasons Hotel, New York, NY
Thursday, September 10, 2009
8:30 a.m. ET
Rick E Winningham, Chief Executive Officer

Morgan Stanley Global Healthcare Unplugged Conference
Grand Hyatt, New York, NY
Tuesday, September 15, 2009
1:35 p.m. ET
Michael W. Aguiar, Senior Vice President and Chief Financial Officer

ThinkEquity 6th Annual Growth Conference
The St. Regis Hotel, San Francisco, CA
Thursday, September 17, 2009
10:30 a.m. PT
Rick E Winningham, Chief Executive Officer

Bank of America Merrill Lynch 2009 Smid Cap Conference
InterContinental, Boston, MA
Tuesday, September 22, 2009
9:40 a.m. ET
Rick E Winningham, Chief Executive Officer

UBS Global Life Sciences Conference
Grand Hyatt, New York, NY
Wednesday, September 23, 2009
8:00 a.m. ET
Rick E Winningham, Chief Executive Officer

All webcast information will be available on Theravance's web site at www.theravance.com. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

About Theravance

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. The company's key programs include: telavancin for the treatment of serious Gram-positive bacterial infections with Astellas Pharma Inc. and the Horizon program and Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with GlaxoSmithKline plc. By leveraging its proprietary insight of multivalency toward drug discovery focused primarily on validated targets, Theravance is pursuing a next generation strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit the company's web site at www.theravance.com.

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.

Theravance's presentations will contain certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to the goals and timing of clinical studies, statements regarding the potential benefits and mechanisms of action of drug candidates, statements concerning the goals and timing of seeking regulatory approval of our product candidates (including with respect to telavancin statements regarding any expectation that regulatory authorities will approve telavancin on the basis of existing preclinical and clinical data or at all), statements concerning the enabling capabilities of Theravance's approach to drug discovery and its proprietary insights, statements concerning expectations for product candidates through development and commercialization and projections of revenue and other financial items. These statements are based on the current estimates and assumptions of the management of Theravance as of the date of the presentations and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance to be materially different from those reflected in its forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to delays or difficulties in commencing or completing clinical studies, the potential that results of clinical or preclinical studies indicate product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals for, or to successfully launch, product candidates, risks of relying on third-party manufacturers for the supply of our product candidates and risks of collaborating with third parties to develop and commercialize products. These and other risks are described in greater detail under the heading "Risk Factors" contained in Theravance's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 5, 2009 and the risks discussed in our other periodic filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance assumes no obligation to update its forward-looking statements.

Contact Information

  • Contact Information:

    Michael W. Aguiar
    Senior Vice President and CFO
    650-808-4100
    Email Contact